Related Experiment Videos
Setting threshold limits for the significance of objectionable microorganisms in oral pharmaceutical products
W Manu-Tawiah1, B A Brescia, E R Montgomery
1Dupont Pharmaceuticals Company. Wireko.Manu-Tawiah@dupontpharma.com
Abstract:
Due to the increasing number of immuno-compromised patients, increased attention is paid to the quantitation and identification of microorganisms in oral pharmaceutical products; therefore, a systematic approach is required by the manufacturers of non-sterile oral pharmaceuticals to evaluate the significance of microbial isolates other than primary pathogens and/or those in the product specification based on the number of organisms present, the type of dosage form, and the potential hazard to the user. Limits for objectionable microorganisms in oral products intended for use by immuno-compromised patient populations such as pediatric, HIV, cancer, etc., must be tighter than the limits for oral products intended for treating patients with diseases or conditions not affecting their immune systems because patients with deficient immune systems are more at risk of microbial infections. Smaller numbers of opportunistic pathogens become infectious when resistance mechanisms are impaired, either by severe underlying disease, or by use of immunosuppressive drugs. This article proposes a systematic approach for evaluating the significance of microbial isolates other than primary pathogens and/or those in the specification (e.g., Staphylococcus aureus and Pseudomonas aeruginosa) of non-sterile oral pharmaceutical products by setting appropriate threshold limits.
Insights
Manufacturers need a systematic approach to assess microbial contamination in oral pharmaceuticals, especially for immunocompromised patients. This ensures product safety by setting appropriate limits for microorganisms beyond primary pathogens.
Area of Science:
- Pharmaceutical Microbiology
- Drug Safety Evaluation
Background:
- Increasing immunocompromised patient populations necessitate stricter microbial control in pharmaceuticals.
- Oral pharmaceutical products require robust evaluation of microbial contaminants, particularly non-pathogenic isolates.
- Existing specifications may not adequately address risks for vulnerable patient groups.
Purpose of the Study:
- To propose a systematic approach for evaluating microbial isolates in non-sterile oral pharmaceuticals.
- To establish appropriate threshold limits for microorganisms, considering patient risk.
- To enhance the safety of oral medications for immunocompromised individuals.
Main Methods:
- Developing a risk-based framework for microbial assessment.
- Considering factors like organism quantity, dosage form, and potential user hazard.
- Defining limits for objectionable microorganisms beyond primary pathogens.
Main Results:
- A systematic methodology for evaluating microbial significance in oral pharmaceuticals.
- Recommendations for setting tighter limits for products targeting immunocompromised patients.
- Guidance on assessing isolates not typically listed in product specifications.
Conclusions:
- A systematic approach is crucial for ensuring the safety of oral pharmaceuticals for all patient populations.
- Tailored microbial limits are essential for immunocompromised individuals due to increased infection risk.
- This framework aids manufacturers in managing microbial quality and patient safety effectively.